Last reviewed · How we verify
HNC042 single dose
At a glance
| Generic name | HNC042 single dose |
|---|---|
| Sponsor | Guangzhou Henovcom Bioscience Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HNC042 single dose CI brief — competitive landscape report
- HNC042 single dose updates RSS · CI watch RSS
- Guangzhou Henovcom Bioscience Co. Ltd. portfolio CI